论文部分内容阅读
为了探讨ＣｓＡ谷浓度（ＴＬ）与临床急性排异和中毒的关系，我们对我院１９９０年５月至１０月４６例肾移植病人（男３８例、女８例）术后１０９次系列ＣｓＡ－ＴＬ进行了分析。结果：肾移植术后系列测定全血ＣｓＡＴＬ对急性排异和ＣｓＡ中毒的诊断有帮助。三联疗法（Ｐｒｅｄ＋ＣｓＡ＋Ａｚａ）与二联疗法（Ｐｒｅｄ＋Ａｚａ）的治疗窗不同。术后３月内，二联疗法合适的治疗窗是２００－４００ｎｇ／ｍｌ，当ＣｓＡ－ＴＬ ２００ｎｇ／ｍｌ，７８．２６／病人出现急性排异，而当ＣｘＡ－ＴＬ＞４００ｎｇ／ｍｌ，则３３．３％与ＣｓＡ肾中毒相联系。二联疗法合适的治疗窗是２５０－５００ｎｇ／ｍｌ，当ＣｓＡ－Ｔｌ ２５０ｎｇ／ｍｌ．６４％出现急性排异，ＴＬ＞５００ｎｇ／ｍｌ，急性ＣｓＡ肾中毒发生率４０％。当ＣｓＡ－ＴＬ＞６００ｎｇ／ｍｌ，三联与二联疗法的感染率分别是３３．３３％和３８．０９％。
To investigate the relationship between CsA trough concentration (TL) and clinical acute rejection and poisoning, we investigated the effect of 109 series of CsA-1 in renal transplant patients (38 males and 8 females) from May 1990 to October 1990 in our hospital. TL was analyzed. Results: The serial determination of whole blood CsATL after renal transplantation is helpful for the diagnosis of acute rejection and CsA poisoning. The triple therapy (Pred + CsA + Aza) differs from the therapeutic window for dual therapy (Pred + Aza). Within 3 months after surgery, the appropriate therapeutic window for dual therapy was 200-400 ng / ml, with acute rejection of CsA-TL at 200 ng / ml and 78.26 / patient, whereas when CxA-TL> 400 ng / ml, .3% Linked to CsA nephrotoxicity. A suitable therapeutic window for dual therapy is 250-500 ng / ml when CsA-Tl 250 ng / ml. 64% appeared acute rejection, TL> 500ng / ml, the incidence of acute CsA nephrotoxicity 40%. When CsA-TL> 600ng / ml, the infection rates of triple and dual therapy were 33.33% and 38.09% respectively.